Biopharmaceutical News and Research

RSS

Insilico to present advances in artificial intelligence at the Healthcare Innovation Summit Africa 2018

Insilico Medicine, a Rockville-based leader in next-generation artificial intelligence for drug discovery, biomarker development, and aging research, is pleased to announce the talk of its Head of Africa Artificial Intelligence for Healthcare Initiative, Iraneus Ogu, who will present alongside other academic thought leaders and industry experts at the 4th Healthcare Innovation Summit Africa 2018, one of the largest healthcare events in Africa.

12 Oct 2018

Eight promising biomedical research projects receive ASH Bridge Grants

Today, ASH announced the names of eight investigators who have each been awarded $150,000 through the ASH Bridge Grant Program.

12 Oct 2018

PAREXEL develops several new patient-centric solutions to address drug development

PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced that it has developed several new solutions that take a patient-centric approach to addressing drug development.

From Parexel 10 Oct 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany.

10 Oct 2018

Arcus Biosciences announces presentation of final results from Phase 1 study of AB928 at ESMO 2018

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology 2018 Congress, being held October 19-23, 2018, in Munich, Germany.

8 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Blackstone to acquire leading life sciences investment firm, Clarus

Blackstone today announced that it has agreed to acquire Clarus, a leading global life sciences investment firm that has raised $2.6 billion since its founding. Clarus, with offices in the life sciences hubs of Boston and San Francisco, is focused on funding growth-stage investments, often in partnership with major biopharmaceutical companies through R&D collaborations.

5 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, announces the availability of Brightplex, a novel high capacity IHC multiplex technology enabling multiple biomarkers to be analyzed on a single FFPE slide.

4 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Therapure Biomanufacturing, an integrated contract development and manufacturing organization and a division of Therapure Biopharma Inc., today announced approval for the manufacturing of Insmed Incorporated's ARIKAYCE® at its Mississauga facility by the U.S. Food and Drug Administration.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

BHCGC consortium to play key role in NIH's large-scale effort to advance precision medicine

The Baylor College of Medicine Human Genome Sequencing Center today announced participation in the National Institutes of Health All of Us Research Program, a large-scale effort to advance precision medicine.

27 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer cell therapy, today announced it has received a favorable response from the U.S. Food and Drug Administration to its pre-Investigational New Drug meeting package for the proposed Phase 2 trial of CytoSen's adoptive NK cell therapy, CSTD002-NK, for the reduction of relapse in high risk acute myeloid leukemia or myelodysplastic syndrome in patients undergoing haploidentical hematopoietic stem cell transplantation.

27 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Crown Bioscience announces successful validation of well-characterized prostate cancer PDX models

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft models of prostate cancer.

27 Sep 2018

Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US

Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.

24 Sep 2018

Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone

Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.

24 Sep 2018

Biopharmaceutical News and Research

Insilico to present advances in artificial intelligence at the Healthcare Innovation Summit Africa 2018

Eight promising biomedical research projects receive ASH Bridge Grants

PAREXEL develops several new patient-centric solutions to address drug development

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Arcus Biosciences announces presentation of final results from Phase 1 study of AB928 at ESMO 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Blackstone to acquire leading life sciences investment firm, Clarus

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

BHCGC consortium to play key role in NIH's large-scale effort to advance precision medicine

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Crown Bioscience announces successful validation of well-characterized prostate cancer PDX models

Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US

Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News